Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

November 04, 2010

The progesterone derivative MPA triggers in vivo RANKL expression and the proliferation of mammary epithelial cells as well as mammary tumorigenesis through RANK. a, Induction of RANKL expression by MPA. Nulliparous wild-type females were implanted subcu

Progestins, used in contraceptives and hormone replacement therapy, have been epidemiographically linked to breast cancer. We have now found a mechanistic basis for this association and could show in a mouse model that synthetic progestins can promote mammary tumour formation by inducing the osteoclast differentiation factor RANKL, which acts on mammary epithelial cells through the RANKL receptor RANK. This then triggers uncontrolled proliferation and protection against DNA damage-induced cell death of mammary epithelial cells. Moreover, we could show a crucial role of the RANKL/RANK system in normal stem cell proliferation and expansion during pregnancy as well as in self renewal of tumor-inducing cancer stem cells. These findings were also confirmed by Gonzalez-Suarez et al., who published in a back-to-back paper that inhibition of RANKL reduces tumorigenesis in the same hormone-induced as well as in other mouse mammary gland tumour models, indicating that an anti-RANKL therapy might also proof effective in human trials. Denosumab, a monoclonal anti-RANKL Ab, has already proofen to be effective in treating bone loss in post-menopausal osteoporosis and in cancer patients with  skeletal-related symptoms and could therefore be now easily tested in breast cancer patients.  

>>link to article on Nature website

>>find out more about the Penninger Lab

The Vienna Biocenter in the third district of Vienna has established itself as the premier location for life sciences in Central Europe and is a world-leading international bio-medical research center.


visit the Website